Rafael Holdings CFO Departs, New CFO Appointed
Ticker: RFL · Form: 8-K · Filed: Aug 7, 2025 · CIK: 1713863
Sentiment: neutral
Topics: executive-change, cfo-appointment, personnel
Related Tickers: RFL
TL;DR
CFO David Gury out, Jonathan Gury in at Rafael Holdings. Big changes ahead?
AI Summary
On August 4, 2025, Rafael Holdings, Inc. filed an 8-K report detailing the departure of its Chief Financial Officer, Dr. David J. Gury, effective August 1, 2025. The company also announced the appointment of Mr. Jonathan S. Gury as the new Chief Financial Officer, effective August 1, 2025. Additionally, the filing includes information regarding compensatory arrangements for certain officers.
Why It Matters
This filing indicates a change in key financial leadership at Rafael Holdings, which could impact the company's financial strategy and investor confidence.
Risk Assessment
Risk Level: medium — Changes in key executive positions, especially the CFO, can introduce uncertainty and potential shifts in financial strategy.
Key Players & Entities
- Rafael Holdings, Inc. (company) — Registrant
- Dr. David J. Gury (person) — Departing Chief Financial Officer
- August 1, 2025 (date) — Effective date of CFO departure and appointment
- Mr. Jonathan S. Gury (person) — Appointed Chief Financial Officer
- August 4, 2025 (date) — Date of report
FAQ
Who has been appointed as the new Chief Financial Officer of Rafael Holdings, Inc.?
Mr. Jonathan S. Gury has been appointed as the new Chief Financial Officer, effective August 1, 2025.
When did Dr. David J. Gury's departure as CFO become effective?
Dr. David J. Gury's departure as Chief Financial Officer became effective on August 1, 2025.
What is the exact name of the registrant filing this report?
The exact name of the registrant is Rafael Holdings, Inc.
What is the state of incorporation for Rafael Holdings, Inc.?
Rafael Holdings, Inc. is incorporated in Delaware.
What are the main items reported in this 8-K filing?
This 8-K filing reports on the departure of a director or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers, as well as financial statements and exhibits.
Filing Stats: 1,088 words · 4 min read · ~4 pages · Grade level 10.6 · Accepted 2025-08-07 16:30:30
Key Financial Figures
- $0.01 — tered Class B common stock, par value $0.01 per share RFL New York Stock Exchan
- $428,000 — Fine's base salary will be increased to $428,000 per annum and Mr. Fine will be granted
- $25,000 — n stock, with a value of the options of $25,000 on the date of grant. The foregoing su
- $852,168 — ther things: (i) a severance payment of $852,168 which shall be paid by the Company in t
- $218,195 — will receive severance in the amount of $218,195 and, in lieu of any entitlement for a p
- $100,000 — he Company providing for annual fees of $100,000 and the accelerated vesting, one day fo
Filing Documents
- ea0252232-8k_rafael.htm (8-K) — 46KB
- ea025223201ex10-1_rafael.htm (EX-10.1) — 12KB
- ea025223201ex10-2_rafael.htm (EX-10.2) — 35KB
- 0001213900-25-073104.txt ( ) — 317KB
- rfl-20250804.xsd (EX-101.SCH) — 4KB
- rfl-20250804_def.xml (EX-101.DEF) — 26KB
- rfl-20250804_lab.xml (EX-101.LAB) — 36KB
- rfl-20250804_pre.xml (EX-101.PRE) — 25KB
- ea0252232-8k_rafael_htm.xml (XML) — 6KB
02 Departure of Directors or Certain Officers; Election
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On August 4, 2025, John Goldberg resigned as the Chief Medical Officer of Rafael Holdings, Inc. (the "Company"), effective July 31, 2025. (c) On August 4, 2025, Joshua Fine was elected as the Company's Chief Operating Officer. Joshua Fine, age 43, has served as Chief Financial Officer of Cyclo Therapeutics, LLC (formerly Cyclo Therapeutics, Inc., which since March 2025 has been a wholly owned subsidiary of the Company), since June 2019. Mr. Fine previously served as Vice President of Finance and Operations of Icagen, Inc. from 2017 until it was wound down in November 2020 after the successful sale of its assets, and Vice President/Director, Healthcare Capital Markets of Scarsdale Equities, LLC from 2011 to 2017. Joshua Fine received his Bachelor of Arts in Political Science from Hartwick College. Joshua Fine is the son of N. Scott Fine who serves as an ex-officio director of the Company and Vice Chairman of the Company's Board of Directors. In connection with Joshua Fine's election as the Company Chief Operating Officer, he and the Company entered into a Novation and Amendment (the "Amendment") to the Amended and Restated Executive Employment Agreement between Joshua Fine and Cyclo Therapeutics, Inc. (which amended and restated employment agreement was previously filed as an exhibit to Amendment No. 4 to the Company's Registration Statement on S-4 filed with the Securities and Exchange Commission ("SEC") on February 11, 2025) pursuant to which Mr. Fine's base salary will be increased to $428,000 per annum and Mr. Fine will be granted options to purchase shares of the Company's Class B common stock, with a value of the options of $25,000 on the date of grant. The foregoing summary of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, a copy of
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Document 10.1 Novation and Amendment to the Amended and Restated Executive Employment Agreement between Joshua Fine and Cyclo Therapeutics, Inc., dated August 6, 2025. 10.2 General Release Agreement, dated August 4, 2025, between the Company and N. Scott Fine. 104 Cover Page Interactive Data File, formatted in Inline XBRL document. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RAFAEL HOLDINGS, INC. By: /s/ David Polinsky Name: David Polinsky Title: Chief Financial Officer Dated: August 7, 2025 2 EXHIBIT INDEX Exhibit No. Document 10.1 The Novation and Amendment to the Amended and Restated Executive Employment Agreement between Mr. Joshua Fine and Cyclo Therapeutics, Inc., dated August 6, 2025. 10.2 General Release Agreement, dated August 4, 2025, between the Company and N. Scott Fine. 104 Cover Page Interactive Data File, formatted in Inline XBRL document. 3